JPMorgan downgraded Pliant Therapeutics (PLRX) to Neutral from Overweight without a price target after the company announced a voluntary pause ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback